QIPT · As filed with the SEC
Quipt Home Medical income statement, by quarter
The statement as Quipt Home Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF INCOME (LOSS) (UNAUDITED) · USD, except per-share amounts
| USD, except per-share amounts | Q1 FY26 3 months ended Dec 31, 2025 | Q4 FY25 3 months ended Sep 30, 2025 | Q3 FY25 3 months ended Jun 30, 2025 | Q2 FY25 3 months ended Mar 31, 2025 | Q1 FY25 3 months ended Dec 31, 2024 | Q4 FY24 3 months ended Sep 30, 2024 | Q4 FY23 3 months ended Sep 30, 2023 | Q4 FY22 3 months ended Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Rentals of medical equipment | 31,984,000 | — | 23,228,000 | 24,028,000 | 24,321,000 | — | — | — |
| Sales of medical equipment and supplies | 49,012,000 | — | 35,061,000 | 33,348,000 | 37,060,000 | — | — | — |
| Total revenue | 80,996,000 | — | 58,289,000 | 57,376,000 | 61,381,000 | — | — | — |
| Cost of inventory sold | 22,775,000 | — | 14,873,000 | 15,136,000 | 17,767,000 | — | — | — |
| Operating expenses | 41,571,000 | — | 31,041,000 | 29,893,000 | 30,398,000 | — | — | — |
| Depreciation | 10,882,000 | — | 9,758,000 | 9,829,000 | 9,473,000 | — | — | — |
| Amortization of intangible assets | 1,671,000 | — | 1,481,000 | 1,547,000 | 1,521,000 | — | — | — |
| Right-of-use operating lease amortization and interest | 1,869,000 | — | 1,585,000 | 1,632,000 | 1,536,000 | — | — | — |
| Stock-based compensation | 982,000 | — | 2,120,000 | 298,000 | 207,000 | — | — | — |
| Acquisition-related costs | 292,000 | — | 126,000 | 48,000 | 47,000 | — | — | — |
| Gain on disposals of property and equipment | (70,000) | — | (872,000) | (8,000) | (16,000) | — | — | — |
| Operating income | 1,024,000 | — | (1,823,000) | (999,000) | 448,000 | — | — | — |
| Interest expense | 1,825,000 | — | 1,595,000 | 1,666,000 | 1,764,000 | — | — | — |
| Interest income | (61,000) | — | (101,000) | (128,000) | (154,000) | — | — | — |
| Change in fair value of derivative liability - interest rate swaps | (24,000) | — | 182,000 | 414,000 | (1,038,000) | — | — | — |
| Loss (gain) on foreign currency transactions | (73,000) | — | (610,000) | (11,000) | 853,000 | — | — | — |
| Share of loss in equity method investment | 46,000 | — | 101,000 | 67,000 | 77,000 | — | — | — |
| Loss before income taxes | (689,000) | — | (2,990,000) | (3,007,000) | (1,054,000) | — | — | — |
| Provision for income taxes | 25,000 | — | 35,000 | 35,000 | 30,000 | — | — | — |
| Net loss before noncontrolling interest | (714,000) | — | — | — | — | — | — | — |
| Net income attributable to noncontrolling interest | 339,000 | — | — | — | — | — | — | — |
| Net loss | (1,053,000) | — | (3,025,000) | (3,042,000) | (1,084,000) | — | — | — |
| Net loss per share | ||||||||
| Basic loss per share | (0.02) | — | (0.07) | (0.07) | (0.03) | — | — | — |
| Diluted loss per share | (0.02) | — | (0.07) | (0.07) | (0.03) | — | — | — |
| Weighted average number of common shares outstanding: | ||||||||
| Basic (in shares) | 43,609 | — | 43,459 | 43,170 | 43,091 | — | — | — |
| Diluted (in shares) | 43,609 | — | 43,459 | 43,170 | 43,091 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.